多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效分析

Efficacy analysis of docetaxel combined with carboplatin versus paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer

目的分析多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌患者的临床效果。方法100例晚期卵巢癌患者,按照治疗方式不同分为对照组和观察组,每组50例。对照组患者选择多西他赛联合卡铂治疗,观察组患者选择紫杉醇联合顺铂治疗。比较两组患者临床疗效以及治疗前后血管内皮生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)水平。结果观察组病情总控制率82.00%与对照组的80.00%比较,差异无统计学意义(P>0.05)。对照组治疗前的VEGF、MMP-2水平分别为(712.55±44.66)pg/ml、(590.88±44.88)mg/ml,治疗后分别为(187.33±21.55)pg/ml、(248.66±31.89)mg/ml;观察组治疗前的VEGF、MMP-2水平分别为(713.56±44.67)pg/ml、(592.77±44.34)mg/ml,治疗后分别为(186.77±21.93)pg/ml、(246.77±30.65)mg/ml。治疗前后,两组患者VEGF、MMP-2水平组间比较,差异均无统计学意义(P>0.05);但两组治疗后的VEGF、MMP-2水平均低于治疗前,差异均具有统计学意义(P<0.05)。结论多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌患者都有很好的临床效果,并没有明显差异,都值得在临床上推广。

Objective To analyze the clinical effect of docetaxel combined with carboplatin versus paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer.Methods A total of 100 cases of advanced ovarian cancer patients were divided into control group and observation group according to different treatment methods,with 50 cases in each group.Patients in the control group were treated with docetaxel and carboplatin,and patients in the observation group were treated with paclitaxel and cisplatin.The clinical efficacy,vascular endothelial growth factor(VEGF)and matrix metalloproteinase-2(MMP-2)before and after treatment were compared between the two groups.Results The overall disease control rate 82.00%in the observation group was not statistically significant compared with 80.00%in the control group(P>0.05).In the control group,the levels of VEGF and MMP-2 were(712.55±44.66)pg/ml and(590.88±44.88)mg/ml before treatment,and those were(187.33±21.55)pg/ml and(248.66±31.89)mg/ml after treatment;in the observation group,the levels of VEGF and MMP-2 were(713.56±44.67)pg/ml and(592.77±44.34)mg/ml before treatment,and those were(186.77±21.93)pg/ml and(246.77±30.65)mg/ml after treatment.Before and after treatment,there was no statistically significant difference in the levels of VEGF and MMP-2 between the two groups(P>0.05).However,the levels of VEGF and MMP-2 in both groups after treatment were lower than those before treatment in this group,and the differences were statistically significant(P<0.05).Conclusion Docetaxel combined with carboplatin and paclitaxel combined with cisplatin both have good clinical results in treating patients with advanced ovarian cancer,and there is no significant difference,and both are worthy of clinical promotion.